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Abstract
Amyotrophic lateral sclerosis (ALS) is a neurodegenerative disease resulting in severe muscle weakness and eventual death
by respiratory failure. Although little is known about its pathogenesis, mutations in fused in sarcoma/translated in
liposarcoma (FUS) are causative for familial ALS. FUS is a multifunctional protein that is involved in many aspects of RNA
processing. To elucidate the role of FUS in ALS, we overexpressed wild-type and two mutant forms of FUS in HEK-293T cells,
as well as knocked-down FUS expression. This was followed by RNA-Seq to identify genes which displayed differential
expression or altered splicing patterns. Pathway analysis revealed that overexpression of wild-type FUS regulates ribosomal
genes, whereas knock-down of FUS additionally affects expression of spliceosome related genes. Furthermore, cells
expressing mutant FUS displayed global transcription patterns more similar to cells overexpressing wild-type FUS than to
the knock-down condition. This observation suggests that FUS mutants do not contribute to the pathogenesis of ALS
through a loss-of-function. Finally, our results demonstrate that the R521G and R522G mutations display differences in their
influence on transcription and splicing. Taken together, these results provide additional insights into the function of FUS
and how mutations contribute to the development of ALS.
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Introduction
Amyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative
disease affecting upper and lower motor neurons causing pro-
gressive muscle weakness. Patients typically die within three to five
years after onset of symptoms due to respiratory failure [1].
Although most cases are sporadic, approximately 10% of ALS
cases are familial (FALS). Mutations in several genes are causative
for FALS, including fused in sarcoma/translated in liposarcoma
(FUS), superoxide dismutase-1 (SOD1), TAR DNA-binding protein
(TARDBP), angiogenin (ANG), vesicle-associated membrane pro-
tein B (VAPB), optineurin (OPTN), and valosin-containing protein
(VCP) [2,3]. Recently, an expanded hexanucleotide repeat
(GGGGCC) within chromosome 9 open reading frame 72
(C9ORF72) has also been identified in a large percentage (23.5–
46%) of patients with ALS and frontotemporal dementia (FTD),
and additionally, mutations in profilin 1 (PFN1) have been
reported in patients with ALS [4–6].
Mutations in FUS are detected in ,4% of FALS patients and
infrequently in sporadic ALS (SALS) cases [7,8]. FUS is also
known as heterogeneous nuclear ribonucleoprotein (hnRNP) P2
and is involved in numerous aspects of RNA processing [8,9]. The
FUS protein is 526 amino acids long and contains an N-terminal
serine, tyrosine, glycine and glutamine (SYGQ)-rich region, an
RNA-recognition motif (RRM), a C2/C2 zinc finger motif,
multiple arginine, glycine, and glycine (RGG)-repeat regions and
a nuclear localization signal (NLS) at the extreme C-terminus
[8,10]. Together with Ewing’s sarcoma (EWS) and RNA poly-
merase II, TATA box binding protein (TBP)-associated factor,
68 kDa (TAFII68/TAF15), FUS belongs to a family called TET
or FET. Since the vast majority of the ALS mutations occur in the
NLS (amino acids 514–526) and result in cytoplasmic retention of
FUS protein, mutations could impair its function or lead to a toxic
gain-of-function [11,12]. Even though mutations in FUS account
for only a small fraction of FALS and SALS patients, it has been
suggested that FUS protein may be a common component of
cellular inclusions in non-SOD1 ALS and other neurodegenera-
tive conditions [13]. Cytosolic mislocalization of FUS has already
been shown to kindle misfolding of wild-type SOD1 in non-SOD1
ALS, implying a shared pathogenic pathway underlying SALS,
non-SOD1 FALS, ALS/FTD, and related disorders [13,14].
PLOS ONE | www.plosone.org 1 April 2013 | Volume 8 | Issue 4 | e60788
Given the role of FUS in RNA processing, it could be
hypothesized that mutant FUS contributes to ALS by altering
expression of many genes. A very recent study did identify more
than 5,500 RNA targets of FUS in mouse and human brain, and
showed that depletion of FUS changed at least 600 mRNA levels
and 350 splicing patterns [15]. However, the influence of
overexpressed wild-type and mutant forms of FUS on global
expression has yet to be determined. Towards this goal, we have
performed RNA-Seq on cells expressing exogenous wild-type FUS,
two mutant forms of FUS (R521G, R522G) or small interfering
RNA (siRNA) against FUS. The results of this study yield insights
into the normal pathways influenced by wild-type FUS and how
mutations lead to the pathogenesis of ALS.
Materials and Methods
Plasmid Constructs
Human wild-type FUS (clone MGC-8537, Invitrogen, Carlsbad,
CA) was inserted into a pcDNA3.1 vector containing an N-
terminal V5 (Invitrogen) epitope tag with BP and LR Clonase kits
(Invitrogen). Mutations located in exon 15 (p.Arg521Gly (R521G
[c.C1561G]) and p.Arg522Gly (R522G [c.C1564G])) were
generated by using QuikChange II Site-Directed Mutagenesis kit
(Stratagene, La Jolla, CA). Sequencing was used to verify the
orientation of the inserts and absence of polymerase chain reaction
(PCR)-induced mutations.
Cell Culture
HEK-293 cells optimized for transfections (HEK-293T) were
cultured in Dulbecco’s Modified Eagle’s medium (DMEM)
supplemented with 10% fetal calf serum and 4 mM L-glutamine.
Transfections were performed with Lipofectamine 2000 trans-
fection reagent (Invitrogen) according to the manufacturer’s
recommendations. Cells were transfected with either 4 mg of
expression constructs or 50.0 rmol Silencer pre-designed siRNA
directed against FUS (s5402, Applied Biosystems, Carlsbad, CA).
To test the efficiency of transfections, cells were co-transfected
with 0.4 mg enhanced green fluorescent protein (pEGFP-C1)
plasmid, which expressed GFP (Clontech, Mountain View, CA).
After 24 hours the medium was changed to DMEM and cells were
analyzed at 48 hours post-transfection. Transfection efficiencies for
all conditions were greater than 75%, as determined by
immunofluorescence staining.
Preparation of Cell Lysates
Transfected cells were washed in phosphate-buffered saline
(PBS) and then detached with a cell scraper. An aliquot of the
cell suspension was centrifuged, resuspended in TENN buffer
(50 mM Tris-HCl [pH 7.4], 5 mM EDTA, 150 mM NaCl,
0.5% Nonidet P-40) with Protease Inhibitor Cocktail (Roche,
Basel, Switzerland) and analyzed by western blot. Western blot
analysis was performed using the following antibodies: rabbit
anti-FUS (1:5,000, Bethyl Laboratories, Montgomery, TX,
A300-302A), mouse anti-V5 (1:5,000, Invitrogen, catalog #
37-7500), rabbit anti-glyceraldehyde 3-phosphate dehydrogenase
(GAPDH, 1:15,000; Abcam, Cambridge, UK, catalog #
Ab22555), Odyssey IRDye anti-rabbit IgG (1:20,000) and
Odyssey IRDye anti-mouse IgG (1:20,000). The Odyssey
Infrared Imaging System (Li-cor, Lincoln, NE) was used for
quantification of western blots. RNA was isolated from the
remaining cell suspension according to the RNeasy Mini Kit
protocol (Qiagen, Hilden, Germany).
RNA-Seq and Data Analysis
RNA-Seq libraries were generated as described previously [16].
Briefly, polyA+ RNA was reverse transcribed using Superscript III
and converted to double-stranded cDNA. Illumina adapters were
ligated and libraries were amplified by PCR and size selected by
gel electrophoresis prior to sequencing on an Illumina Genome
Analyzer (Illumina, San Diego, CA). Analysis of RNA-Seq was
performed utilizing software package ExpressionPlot [17]: gene
expression levels were estimated by counting the number of reads
mapping to constitutive exons for each gene and determining
RPKM values (reads per kilobase of exon model per million
uniquely mapped reads). P-values were calculated using the
Fisher’s exact test for pairwise comparison between samples, which
is shown to be conservative, as described elsewhere [17]. For
skipped exon analysis, P-values were determined based on the
ratio of inclusion reads to the sum of skipping and flanking reads
(Materials and Methods S1 in File S1) using Fisher’s exact test. For
intron retention analysis, P-values were calculated using the
Fisher’s exact test based on the comparison of inclusion and
flanking reads between conditions (Materials and Methods S1 in
File S1). Plots demonstrating the distribution of data by showing
the log intensity ratio (M) and the average log intensity for a dot
(A, [MA plots]) per condition comparison did not display
expression level dependent differential signals (Figure S1 in File
S1).
Events with Ensemble gene identifiers were subjected to further
analysis. For the differential expression analysis, events without
RPKM units were excluded. After Bonferroni multiple test
correction, significant events (P-value ,0.05) were selected and
used to perform functional annotation and functional domain
analysis by Kyoto Encyclopedia of Genes and Genomes (KEGG)
pathway analysis. Details of all significant events can be found in
the Supplementary spreadsheet in File S2. To avoid length-
dependent bias [18], two different background lists were initially
utilized: the Homo sapiens background list as supplied by Database
for Annotation, Visualization and Integrated Discovery (DAVID)
Functional Annotation Tool (http://david.abcc.ncifcrf.gov/home.
jsp) and the list generated from cells transfected with the vector
alone. However, the results from the two approaches displayed few
differences. Therefore, only analysis using the Homo sapiens
background list is reported for all conditions. Venn diagrams
were generated comparing the vector condition to wild-type FUS,
the two FUS mutants and siRNA against FUS, using an online tool
(http://bioinfogp.cnb.csic.es/tools/venny/index.html). Our data
has been deposited to the ExpressionPlot Web Server (http://als-
research.dyndns-server.com/cgi-bin/expressionplot/home.pl)
[17], and will be accessible from the date of publication.
PCR
To confirm gene expression levels detected by RNA-Seq, we
performed quantitative real-time PCR (qRT-PCR) with SYBR
Green PCR mix (Qiagen), according to the manufactures
guidelines. Expression was compared between our conditions
(wild-type FUS, siRNA, mutants and vector alone; the same
samples were used for RT-PCR and RNA-Seq). Six differentially
expressed genes displaying at least one comparison with a minimal
log2 fold change in expression of 0.4 (.1.32 fold change) were
chosen for confirmation by RT-PCR (File S2). The following PCR
program was used: denaturation at 95uC for five minutes followed
by 35 cycles of denaturation at 95uC, annealing at 58/60uC, and
extension at 72uC, each for 30 seconds. Primer pairs used for this
reaction are as follows: (1) RNA binding motif protein 25 (RBM25)
ATGAGCATTATGGCTCCTGCTCCA/TGCTTTCCATT-
CATCCAGCTGTGC, (2) TAF15 TCCTTCAGCTAAGG-
RNA-Seq Analysis of FUS Mutations in ALS
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CAGCCATTGA/GGCTCATTGCACTGATTGCAGGAA, (3)
threonyl-tRNA synthetase (TARS) TTTGAGGATGAG-
GAAGCTCAGGCA/TTGCCCGTGTGTCTAACATGAGGA,
(4) translocated promoter region, nuclear basket protein (TPR)
AACAACTCCGCAAATCACGACAGC/TGTTTAAGGG-
CAGCCTTAGCCTCT, (5) amyloid beta (A4) precursor protein
(APP) ACCAACCAGTGACCATCCAGAACT/CAGCAA-
CATGCCGTAGTCATGCAA, and (6) hematological and neu-
rological expressed 1 (HN1) TGGGTTTACCAAGCCT-
CAACTGGA/AGGAAGACCCGCTTCAGTGTGATT. For
differential expression analysis, threshold cycle (Ct) values were
collected in quadruplicate for each condition, and delta-Ct values
were normalized using GAPDH values for the same condition.
Hereafter, the average Ct value for the reference condition was
subtracted from the normalized Ct values (delta-delta-Ct) and the
fold decrease change was calculated (2ˆ(delta-delta-Ct)). Sub-
sequently, the relative expression and log2 fold changes were
determined.
For the confirmation of alternative splicing RNA-Seq results,
semi-quantitative PCR was performed using primers derived from
the upstream and downstream exons. Two genes (PRPF8 and
RPS24) displaying a minimal log2 fold change in exon exclusio-
n:inclusion of 0.4 (.1.32 fold change) were chosen for confirma-
tion. Quadruplicate reverse transcribed PCR products were
separated on a 2% gel, and bands were analyzed with ImageJ
(http://rsbweb.nih.gov/ij/). For each condition, an unspliced:s-
pliced ratio and log2 fold change were calculated. Primer pairs
used for this reaction are as follows: (1) pre-mRNA-processing-
splicing factor 8 (PRPF8) TTGGGAATCTGGTTCAGTCC/
GGCACACACTGGCTTATGAT, and (2) ribosomal protein S24
(RPS24) ATGAAGAAAGTCAGGGGGACTG/
TAATGTTCTTGCGAAAAATCCAC. A general linear model
was fitted with delta-delta-Ct values or unspliced:spliced values as
dependent variable, and all conditions as categorical independent
variable, using the appropriate condition as reference (e.g. wild-
type FUS, when comparing one mutant with wild-type FUS).
Results
To investigate the global effects of wild-type and mutant FUS
protein on cellular transcription and splicing, HEK-293T cells
were transfected with expression vectors encoding wild-type FUS,
two FUS mutants (R521G and R522G) or siRNA directed against
FUS. Transfection with an empty vector served as a control
condition. RNA-Seq resulted in 24 to 31 million reads for each
transfection condition (Table S1 in File S1). Quality control
assessments revealed that .69.9% of reads uniquely mapped to
the genome and less than 2.72% of reads were derived from
ribosomal RNA (Table S1 in File S1). Analysis of RNA-Seq data
demonstrated that cells expressing either wild-type or mutant FUS
displayed a,2-fold increase in expression, whereas cells harboring
siRNA displayed a ,4-fold decrease in FUS expression (Figure S2
in File S1). Interestingly, western blot analysis of an aliquot of
transfected cells used for RNA-Seq displayed lower levels of
overexpression of FUS mutants relative to the wild-type, suggesting
that post-transcriptional regulation may influence FUS protein
levels (Figure S3 in File S1).
Pathway analysis was performed for differential expressed genes
using the DAVID Functional Annotation Tool (Materials and
Methods). This analysis revealed that overexpression of wild-type
FUS (wild-type FUS vs. vector alone) influences expression of
ribosomal related genes, whereas knock-down of FUS expression
(siRNA vs. vector alone) influences expression of both ribosome
and spliceosome related genes (Table 1, Table S2 in File S1). The
differentially expressed genes encoded several ribosomal proteins,
aspartic acid, glutamic acid, alanine, and aspartic acid (DEAD)
box proteins, RNA-binding motif proteins, hnRNPs, and splicing
factors (Table S3 in File S1). Further analysis revealed that the
differentially expressed genes often encoded proteins containing
RRMs, endoplasmic reticulum (ER) targeting sequences, and
nucleotide-binding alpha-beta plaits (Table S4 in File S1).
To understand the mechanism by which FUS mutants may
contribute to ALS pathogenesis, we determined whether the
expression patterns induced by mutant FUS were more similar to
reduced FUS expression or overexpressed wild-type FUS. Similar-
ity to reduced expression of FUS would suggest that the mutants
act by a loss-of-function mechanism, whereas similarity to
overexpressed wild-type FUS would suggest a gain-of-function
for the mutants. Towards this end, the number of differentially
expressed genes between each of the two FUS mutants and either
siRNA or wild-type FUS conditions was calculated. As shown in
Table 2, both the R521G and R522G mutants displayed an
increased number of differentially expressed genes when com-
pared to reduced FUS expression than to overexpressed wild-type
conditions (P-value ,0.0001 for both). In other words, the
transcriptional profiles of cells expressing this FUS mutant more
closely resembled that of overexpressed wild-type FUS than of
reduced levels of FUS. These results suggested that the FUS
mutants do not contribute to ALS pathogenesis through a loss-of-
function.
To investigate whether the two FUS mutants differed in their
influence on transcription, the direction of change for differentially
expressed genes was compared. Interestingly, although the total
number of genes that was regulated by R521G and R522G was
not significantly different, there was a significant difference in the
number of genes that was up/down-regulated. As shown in
Table 3, R521G dramatically favored up-regulation of the
differentially identified genes, whereas R522G favored down-
regulation. Despite the fact that the two FUS mutants appeared to
have opposite effects on differential gene expression, pathway
analysis revealed that both mutants significantly influenced
spliceosome related genes (Table 1). Additionally, the R522G
mutant also altered ribosome, mismatch repair and DNA
replication related genes. The identified genes encoded, amongst
others, DEAD box proteins, hnRNPs, splicing factors, ribosomal
proteins, exonuclease, replication factors, mini-chromosome
maintenance complex components, and proliferating cell nuclear
antigen (Table S3 in File S1). The most significantly enriched
protein domains were RRMs, nucleotide-binding alpha-beta plaits
and helicases (Table S4 in File S1).
Venn diagrams were generated (Figure 1) to identify genes
shared amongst conditions. When both mutants, wild-type FUS
and siRNA, directed against FUS, were compared to the vector
condition, 13 genes were revealed (Table 4), including HN1,
ribosomal protein S3, S16, S19 (RPS3, RPS16, RPS19), CCR4-
NOT transcription complex, subunit 1 (CNOT1), and RNA
component of mitochondrial RNA processing endoribonuclease
(RMRP).
To assess the reliability of our RNA-Seq differential expression
analysis, we attempted to validate a subset by qRT-PCR. Towards
this end, we selected 10 significant expression differences from 6
different genes observed by our RNA-Seq results (RBM25, TAF15,
TARS, TPR, APP, and HN1) for validation. Through our analysis,
we were able to validate 8 out of the 10 observed expression
changes by qRT-PCR (Figure S4 in File S1), suggesting that our
RNA-Seq results are reliable.
Our analysis was extended to investigate the influence on
alternative splicing, in particular skipped exons. Comparison of
RNA-Seq Analysis of FUS Mutations in ALS
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overexpressed wild-type FUS to vector transfected cells resulted in
only 32 significant events and did not reveal any functional
pathways enriched by these events (Table S2 in File S1). In
contrast, knock-down of FUS expression resulted in 579 significant
changes in skipped exons splicing patterns. These changes were
enriched in ribosome and spliceosome related genes (Table S2 in
File S1). Pathway analysis of the R521G mutant revealed
involvement of ribosome related genes, whereas the R522G
mutant also affected spliceosome related genes (Table S2 in File
S1). Additionally, we detected a small significant difference in the
number of genes that were affected by R521G and R522G
mutations, but there was no significant difference in the direction
of this change (Table 5). Semi-quantitative PCR of two
alternatively spliced genes, PRPF8 and RPS24, demonstrated
similar splicing patterns by both techniques (Figure S5 in File S1).
To further investigate the influence of FUS on alternative
splicing, we similarly analyzed our results for genes displaying
changes in retained introns. Overexpression of wild-type FUS
revealed 3,116 significant retained intron events. Pathway analysis
showed these event were enriched in spliceosome, Huntington’s
disease, proteasome, Parkinson’s disease, oxidative phosphoryla-
tion, cell cycle, DNA replication, and pyrimidine metabolism
related genes (Table S2 in File S1). Down-regulation of FUS
resulted in 3,054 significant retained intron events that were
involved in the same pathways. There was a significant difference
in the number of genes that were affected by R521G and R522G
(P-value 5.2E-08). The direction of this change was significantly
different as well: the R522G mutant displayed increased intron
retention relative to the R521G mutant (Table 6). Pathway
analysis revealed enrichment for genes related to the spliceosome,
Huntington’s disease, proteasome, DNA replication, cell cycle,
pyrimidine metabolism oxidative phosphorylation, and RNA
polymerase (Table S2 in File S1).
We created Venn diagrams to determine which genes were
shared amongst all conditions for both alternative splicing
analyses. A Venn diagram of skipped exon analysis identified
two genes (Figure 2): ribosomal protein L34 (RPL34) and protein
kinase, DNA-activated, catalytic polypeptide (PRKDC). Retained
intron analysis identified 1,099 genes (Figure 3); pathway analysis
of these genes resulted in 15 significant KEGG pathways (Table 7).
The most significant pathways were related to the spliceosome,
Huntington’s disease, DNA replication, the proteasome, and
pyrimidine metabolism (Table S5 in File S1).
Discussion
To study the effects of wild-type and mutant forms of FUS, we
utilized RNA-Seq analysis to investigate alterations in gene
expression and alternative splicing. Our results show that wild-
type FUS affects ribosomal and spliceosome related genes, and
that proteins containing RRMs and nucleotide-binding alpha-beta
plaits were most frequently influenced, confirming the important
role of FUS in RNA processing pathways [8]. This role is
strengthened by previous reports; it has already been shown that
FUS associates with products of RNA polymerase II transcription,
forms complexes with hnRNPs, and represses RNA polymerase III
transcription [19–21]. Furthermore, FUS inhibits the acetyltrans-
ferase activities of CREB-binding protein (CBP) and p300 on
cyclin D1 (CCND1) [22], and regulates the transcription factor
nuclear factor kB (NF-kB) [23,24]. FUS also engages in rapid
nucleocytoplasmic shuttling [25], associates with actin-dependent
Table 1. Functional pathway analysis of differentially expressed genes.
Group KEGG Pathway Count P-value Benjamini and Hochberg, FDR, P-value
Wild-type vs. vector Ribosome 14 5.1E-5 6.6E-3
siRNA vs. vector Spliceosome 34 1.4E-8 2.2E-6
Ribosome 26 1.2E-7 1.0E-5
R521G vs. vector Spliceosome 18 1.0E-8 9.2E-7
R522G vs. vector Ribosome 15 4.0E-7 4.0E-5
Spliceosome 15 3.5E-5 1.8E-3
Mismatch repair 6 8.0E-4 2.7E-2
DNA replication 7 9.1E-4 2.3E-2
FDR= False Discovery Rate.
doi:10.1371/journal.pone.0060788.t001
Table 2. Number of differentially expressed genes by mutant
FUS, FUS overexpression, and FUS knock-down.
Wild-type
(n)
siRNA
(n)
Fisher’s exact, P-
value
R521G Significant 566 863 5.4E-17
Non-significant 17,122 16,511
R522G Significant 1,198 1,937 7.4E-47
Non-significant 16,610 15,583
R521G Up-regulated 509 423 1.3E-62
Down-regulated 57 440
R522G Up-regulated 112 88 1.6E-07
Down-regulated 1,086 1,849
doi:10.1371/journal.pone.0060788.t002
Table 3. The FUS R521G mutant causes increased up-
regulation of genes as compared to the R522G mutant.
R521G
(n) R522G (n)
Fisher’s exact,
P-value
Vector Significant 332 328 0.78
Non-significant 17,052 17,214
Vector Increased expression 297 8 3.7E-134
Decreased expression 35 320
doi:10.1371/journal.pone.0060788.t003
RNA-Seq Analysis of FUS Mutations in ALS
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motor protein myosin Va (MyoVa) [26,27], and is a component of
RNA granules that transport mRNAs [28]. Splicing factors, such
as serine and arginine (SR) proteins, form complexes with FUS
and removal of FUS from the nuclear extract causes disturbances
of the splicing factor equilibrium [29]. Additionally, photoactiva-
table ribonucleoside-enhanced cross-linking and immunoprecipi-
tation (PAR-CLIP) analysis has shown that FUS binds RNA at
high frequency, and preferably near splice acceptors [30]. Very
recently, high-throughput sequencing and computational ap-
proaches demonstrated FUS binding sites in thousands of mouse
and human brain pre-mRNAs [15]. Moreover, in mice, FUS
depletion with single-stranded antisense oligonucleotides (ASOs)
resulted in up-regulation of 275 genes, down-regulation of 355
genes, and 374 splicing events [15].
FUS shows several structural and functional similarities with
transactive response DNA-binding protein 43 (TDP-43) [31].
Mutations in TARDBP, which encodes TDP-43, have been
identified in ,5% of ALS patients [32]. Similar to FUS, the role
of TDP-43 is diverse and includes transcriptional regulation,
splicing inhibition, regulation of mRNA transport, repression of
translation, and mRNA degradation [8]. Recently, it has been
shown that TDP-43 interacts with a diverse spectrum of RNAs
with important functions in the brain [33]. Depletion of TDP-43
from mouse adult brain resulted in a reduction of long introns,
which encode proteins involved in synaptic activity [34]. Deep
sequencing further identified more than 4,300 TDP-43 RNA-
binding partners in rat cortical neurons [35]. These RNA partners
were particularly enriched for genes related to synaptic function,
RNA metabolism, and neuronal development [35]. Thus, RNA
targets of both FUS and TDP-43 emphasize that alterations in
RNA processing pathways play a central role in neurodegenerative
diseases [31,32].
In the present study, we have revealed that FUS mutants are
more similar to overexpression of wild-type FUS than to our
knock-down condition. These results suggest that mutants do not
contribute to ALS pathogenesis through a loss-of-function, and are
supported by recent findings. Caenorhabditis elegans expressing
mutant FUS, for instance, demonstrated adult-onset, age-de-
pendent loss of motility, progressive paralysis and neuronal
degeneration [36]; although mutant phenotypes could be rescued
by methylene blue [37], this could not be established by
Figure 1. Venn diagram of differentially expressed genes. A
comparison between each condition (wild-type FUS, siRNA against FUS
and mutants) and the vector reveals that 13 differentially expressed
genes are shared amongst them (Table 4).
doi:10.1371/journal.pone.0060788.g001
Table 4. Genes shared amongst all conditions for differential expression analysis and skipped exon analysis as shown by Venn
diagrams.
Gene Description
Differential expression HN1 hematological and neurological expressed 1
RPS3 ribosomal protein S3
HSPA5 heat shock 70 kDa protein 5
RPS16 ribosomal protein S16
RPS19 ribosomal protein S19
FLNA filamin A, alpha, actin-binding protein
CNOT1 CCR4-NOT transcription complex, subunit 1, transcription repressor
CALM3 calmodulin 3 (phosphorylase kinase, delta)
NFKB2 nuclear factor of kappa light polypeptide gene enhancer in B-cells 2 (p49/p100)
PLK1 polo-like kinase 1, serine/threonine-protein kinase
RMRP RNA component of mitochondrial RNA processing endoribonuclease
EIF4G2 eukaryotic translation initiation factor 4 gamma, 2
NCL nucleolin, synthesis and maturation of ribosomes
Exon skipping RPL34 ribosomal protein L34
PRKDC protein kinase, DNA-activated, catalytic polypeptide
doi:10.1371/journal.pone.0060788.t004
Table 5. The FUS R521G mutant induces increased skipping
of exons relative to the R522G mutant.
R521G (n) R522G (n)
Fisher’s exact,
P-value
Vector Significant 106 64 0.0031
Non-significant 65,812 63,215
Vector Increased skipping 42 30 0.35
Decreased skipping 64 34
doi:10.1371/journal.pone.0060788.t005
RNA-Seq Analysis of FUS Mutations in ALS
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overexpressing wild-type FUS [38]. These findings are further
substantiated by reports that transgenic mice overexpressing wild-
type FUS developed an aggressive phenotype with limb paralysis
and death by twelve weeks in homozygous animals [39], and that
FUS mutations in Drosophila appeared to cause adult-onset
neurodegeneration via a gain-of-toxicity [40]. Whether mutations
in FUS are indeed causative for ALS through a gain-of-function
mechanism is, however, still a matter of debate, especially since
other studies have advocated a loss-of-function mechanism
[15,32,41–43].
Our analysis also identified differences between R521G and
R522G FUS mutants. Differential expression analysis demon-
strated that these mutations appeared to have opposite effects on
transcriptional regulation. Moreover, both mutations influenced
the spliceosome, but the R522G mutation also altered genes
involved in ribosomal processes, mismatch repair, and DNA
replication. In addition, analysis of skipped exons revealed that
both FUS mutants affected ribosomal genes; the R522G mutant
influenced spliceosome related genes as well. Retained intron
analysis displayed that intron retention was more frequently
detected for R522G than for R521G, suggesting that R522G
mutations cause more profound changes than R521G mutations.
Previously, R521G and R522G mutations have been studied in
several experimental models. Yeast strains have been developed
expressing wild-type and mutant FUS [44–47]. Overexpression of
both resulted in punctuate aggregates in the cytoplasm; R521G
aggregated with very similar kinetics to wild-type FUS in protein
aggregation assays [44–47]. In vitro studies, demonstrated that the
R521G mutant caused a relatively mild cytoplasmic mislocaliza-
tion, whereas R522G caused a strong mislocalization [48]. The
R522G mutant was also investigated in neuroblastoma cells, and
was shown to predominantly accumulate in the cytoplasm and
formed aggregates varying in size and shape [49]. In Caenorhabditis
elegans, the motor function and lifespan of animals expressing
R521G mutations was indistinguishable from wild-type FUS,
whereas R522G mutations caused a significant decrease in motor
function and lifespan [38]. These observations suggest that FUS
mutants may act through differing but converging mechanisms
leading to ALS.
Researchers planning on pursuing differential expression or
altered splicing observations from any transcriptome-wide study
should always confirm results through an alternative method.
Here, we have attempted to address the reliability of our RNA-Seq
data through validation by RT-PCR (differential expression) and
semi-quantitative PCR (exon skipping). Among the specific
molecular targets that were affected by FUS, we validated the
expression patterns of RBM25, TAF15, TARS, TPR, and APP, and
the alternative splicing of PRPF8 and RPS24. In the differential
expression analysis, as well as the skipped exons and retained
introns analyses, proteins with spliceosomal and ribosomal
functions were among the most prominent molecular targets.
These results underscore the function of FUS in the translation of
mRNA to proteins, and splicing of introns from pre-mRNAs,
respectively.
In addition to caveats of analyzing RNA-Seq data on an
individual gene level, we have additionally performed KEGG
pathway analysis. This methodology is highly dependent on the
selection of a proper reference gene list. There is extensive
literature on random lists of genes that appear to be ‘‘enriched’’ for
specific pathways [50], which emphasizes the importance of using
an appropriate reference list. Many studies use a specific platform
to acquire data, which, by definition, could enrich itself. For RNA-
Seq data a potential length-dependent bias has to be considered as
well [18]. We addressed this issue by using both our successfully
sequenced transcripts and the Homo sapiens background list from
DAVID as reference lists; this minimized bias, although we cannot
completely exclude the possibility of residual bias. Furthermore,
technical limitations hampered our ability to detect splicing events,
for instance, our reads were relatively short as compared to the
improved methods that are currently available.
To summarize, we have shown that FUS is implicated in the
regulation of ribosomal and spliceosome related genes, highlight-
Table 6. The FUS R522G mutant induces increased retention
of introns relative to the R521G mutant.
R521G (n) R522G (n)
Fisher’s exact,
P-value
Vector Significant 2,932 2,521 5.2E-08
Non-significant 109,789 109,655
Vector Increased retention 621 1,086 6.3E-68
Decreased retention 2,311 1,435
doi:10.1371/journal.pone.0060788.t006
Figure 2. Venn diagram of genes demonstrating exon skip-
ping. Two overlapping genes are identified when significant splicing
events are compared between conditions (Table 4).
doi:10.1371/journal.pone.0060788.g002
Figure 3. Venn diagram of genes displaying intron retention. A
Venn diagram that compares our conditions to the vector shows that
1,099 retained intron events are shared (Table 7 and Table S5 in File S1).
doi:10.1371/journal.pone.0060788.g003
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ing the importance of RNA processing pathways in the
pathogenesis of ALS. Furthermore, the expression changes
induced by FUS mutants suggest that they do not contribute to
ALS pathogenesis through a loss-of-function. Finally, our results
demonstrate that R521G and R522G mutations display differ-
ences in their influence on transcription and splicing. Taken
together, these observations provide additional insights into the
normal function of FUS and how mutations lead to the
development of ALS.
Supporting Information
File S1 This file includes supporting materials and
methods, Tables S1–S5, and Figures S1–S5. Legends for
Figure S1–S5 are as follows: Figure S1. MA plots per
condition comparison. MA plots per comparison where
M= log (rpkmcondition) – log (rpkmvector) and A= 0.5 * (log
(rpkmcondition)+log (rpkmvector)). Figure S2. FUS gene expres-
sion levels measured by RNA-Seq. Reads per kilobase of
exon model per million uniquely mapped reads (RPKM) counts
are displayed for each condition. Transfections with wild-type
FUS, R521G and R522G resulted in a ,2-fold increase in
expression level, transfections with siRNA in a,4-fold decrease in
expression level. Figure S3. FUS protein levels measured by
western blot. The same samples were used for western blotting
and RNA-Seq. We stained for FUS and the V5-tag (Materials and
Methods), and bands were subsequently detected and quantified
with an Odyssey Infrared Imaging System. For FUS, we
compared each condition to the vector and calculated relative
integrated intensities. We demonstrated that siRNA caused
a decrease in FUS expression (1.0 versus 0.2), whereas transfections
with wild-type FUS and the two mutants caused an increase in
FUS expression (1.0 versus 4.2, 1.8 and 1.1). The multiple bands
detected by FUS antibodies have been observed previously [51].
Figure S4. Correlation of RNA-Seq and RT-PCR for
RBM25, TAF15, TARS, TPR, APP and HN1. We selected 10
differentially expressed conditions within six genes for RT-PCR
validation. These genes required at least one comparison with
a log2 fold change of 0.4 (1.32 fold change). For each comparison,
the log2 fold change and corresponding P-values are shown.
Validation was observed in 8 out of 10 comparisons for 5 out of 6
genes. Figure S5. Correlation of RNA-Seq and Semi-
quantitative PCR for PRPF8 and RPS24. Two alternatively
spliced genes, pre-mRNA-processing-splicing factor 8 (PRPF8) and
ribosomal protein S24 (RPS24), with a log2 fold change in exon
exclusion:inclusion above 0.4, (1.32 fold-change) were selected for
RT-PCR. The log2 fold change and corresponding P-values are
shown. RNA-Seq results were validated by semi-quantitative PCR
in both cases.
(PDF)
File S2 This Excel spreadsheet file contains detail of all
significant events observed from the RNA-Seq analysis.
(XLS)
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